Jade Biosciences to Participate in Upcoming Conferences
Stocks in this Quantisnow insightHealth Care
Historical context for JBIO
Across the 6 sessions after earlier JBIO headlines, the stock closed higher 4 times and lower 2 times, with a median move of 2.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | JBIO | SPY |
|---|---|---|---|
| Jan 7, 2026 | H.C. Wainwright initiated coverage on Jade Biosciences with a new price target | +0.1% | -0.3% |
| Jan 5, 2026 | Jade Biosciences Outlines Key 2026 Objectives and Strategy to Advance Pipeline of Potentially Best-in-Class Monoclonal Antibodies Across Multiple Autoimmune Diseases Ahead of the 44th Annual J.P. Morgan Healthcare Conference | -7.3% | +0.7% |
| Dec 15, 2025 | Jade Biosciences Announces $45 Million Private Placement | +1.8% | -0.2% |
| Nov 14, 2025 | Jade Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update | +10.5% | -0.0% |
| Nov 10, 2025 | Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025 | +1.0% | +1.6% |
| Nov 3, 2025 | Jade Biosciences to Participate in Upcoming Conferences | -3.4% | +0.2% |
Quantisnow market dataNASDAQ
JBIO
Jade Biosciences Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for JBIO
Full JBIO profile on Quantisnow Follow JBIO and get a push notification the moment its next story breaks.